Sign in
Taking people in United StatesNo phase

Saline-enhanced needle ablation for ventricular tachycardia that other treatments have not controlled

Tests a needle ablation device in adults with repeated, treatment-resistant ventricular tachycardia.

Key facts

Who runs it
Thermedical, Inc.
Where
Birmingham, Charleston, Nashville, Philadelphia, and Salt Lake City, United StatesSee the 5 sitesAlso in 1 other country, 2 sites
Trial code
Registry title
Saline Enhanced Radiofrequency (SERF) Needle Ablation for Refractory VT
Status
Recruiting
People taking part
130 people, planned
Started
9 Aug 2025
Expected to end
30 Jun 2027
Type of study
Interventional
Treatments tested
  • Saline Enhanced Radiofrequency (SERF) Ablation
Record updated
14 August 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with structural heart disease whose ventricular tachycardia (a fast, abnormal heart rhythm) keeps coming back despite drugs and earlier catheter ablation. Everyone gets the study ablation device.

Age
18 years or older.
Sex
All sexes can join.
Disease stage
Recurrent symptomatic sustained (> 30 seconds) monomorphic ventricular tachycardia within 180 days before the planned study ablation. At least 3 episodes treated with ATP and/or shock, or at least 2 treated with shock. People must have structural heart disease and an implantable cardioverter-defibrillator (ICD) with a full 6-month record of VT episodes.
Earlier treatment
The VT must have been treated with catheter ablation before. It must have come back despite at least one Class III antiarrhythmic drug after the last ablation, unless that drug was not tolerated or cannot be used. The VT also came back after ablation at a study center, or the doctor documents why a repeat ablation with a standard approved catheter is unlikely to help. No ablation within 4 weeks before the study ablation.

Main reasons for not taking part

  • VT without structural heart disease (idiopathic VT), or VT target outside the left ventricle except the septum
  • LVEF < 20%, NYHA Class IV heart failure, or eGFR <30 ml/min/1.73m2
  • Blood clot inside the heart or fluid around the heart on imaging
  • Heart attack, unstable angina, heart surgery or PCI within the previous 90 days
  • Pregnancy or possible pregnancy, or life expectancy of less than 1 year

The registry criteria, word for word

Show all 34 criteriaShow less

Who can take part

  • Subject has structural heart disease
  • Subject has recurrent symptomatic sustained (> 30 seconds) monomorphic ventricular tachycardia (MMVT) within 180 days prior to planned study ablation that meets the following criteria:; At least 3 episodes of the MMVT have been treated with ATP and/or shock, OR at least 2 episodes were treated with shock AND; Documentation of the presumed recurrent MMVT was treated with prior catheter ablation AND; Occurred despite treatment with at least one Class III antiarrhythmic after last ablation or treatment with a Class III antiarrhythmic is not tolerated or is contraindicated AND; VT has recurred despite VT ablation at one of the investigational centers UORU the investigator documents the reason that the subject is unlikely to benefit from a repeat ablation using a conventional, approved catheter
  • Subject is at least 18 years old
  • Subject has an implantable cardioverter-defibrillator (ICD) with a full 6-month (prior to planned study ablation) ICD interrogation history documenting incidences of VT
  • Subject is able to provide informed consent

Who cannot take part

  • Subject with a prior ablation within 4 weeks of planned study ablation
  • Subject's VT is not amenable to treatment with the study device at the time of mapping for the study ablation
  • Subject with evidence of any right- or left-sided (including left atrium, left atrial appendage and left ventricle) intracardiac thrombus OR pericardial effusion (except chronic trivial) reported on required pre-ablation imaging (CT, MRI, or echocardiography) or seen on required procedural intracardiac echocardiography (ICE) prior to study ablation catheter insertion
  • Subjects with atrial fibrillation/flutter (paroxysmal, persistent, or permanent) without uninterrupted anticoagulation for at least 3 weeks immediately prior to the date of ablation procedure. (Interruption of anticoagulation in the day(s) just prior to ablation will be left to physician decision based upon subject's risk of stroke, anticoagulation agent, renal status, and bleed/embolic risk status with recommendation to consider bridging for high-risk subjects
  • Subject with myocardial infarction (MI) or unstable angina (UA) within previous 90 days
  • Subject with cardiac surgery or percutaneous coronary intervention (PCI) within previous 90 days
  • Subject concurrently enrolled in any other investigational drug or device study that the investigator deems would interfere with study results
  • Subjects with NYHA Class IV heart failure
  • Subject with known coagulopathy or other condition likely to increase risk of periprocedural bleeding
  • Subject with known coagulopathy or other condition likely to increase risk of a thrombotic event
  • Subject with a congenital heart defect except patent foramen ovale (PFO)
  • Subject with known untreated significant ischemic coronary artery disease, acute illness (unrelated to VT or its origin) or active systemic infection
  • Allergy or contraindications to the medications/agents used during a standard ablation/EP intervention including heparin and ionic contrast media
  • Contraindication to cardiac CT
  • Subject with a condition (including a chronic illness) or circumstance that the investigator feels puts the subject at an unacceptable risk for participation in the study or may interfere with quality data collection or study results
  • Idiopathic VT (VT occurring in subjects without structural heart disease [including the absence of LGE on MRI, if performed], metabolic abnormalities or long QT syndrome)
  • Subject has an LVEF < 20% reported on pre-ablation imaging (CT, MRI or echocardiogram within 48 hours of the study procedure)
  • Renal dysfunction with eGFR <30 ml/min/1.73mP2
  • Suspected area of ablation of target clinical VT includes aortic root, aortic cusp or any area outside left ventricle except the ventricular septum
  • Only PVCs are induced during mapping for the study ablation
  • No clinical VT induced during mapping for the study ablation
  • Planned use of a non-study ablation catheter
  • Subject with a mechanical aortic valve, mechanical mitral valve, or MitraClip
  • Subject with flail mitral leaflet or severe aortic stenosis
  • Subject with LAA occlusion device
  • Subject with suspected life expectancy of less than 1 year
  • Subject with left ventricular assist device planned or required for the procedure
  • Females who are or may potentially be pregnant (must be post-menopausal or have a negative pregnancy test)
  • Subject is not willing or is unable to participate in all study procedures and follow-up requirements; -

Where in United States

Also in 1 other country, 2 sites

  • University of Alabama at BirminghamBirmingham, United StatesContact: Sarah HoustonNot yet recruiting
  • Medical University of South CarolinaCharleston, United StatesContact: Kavin PanneerselvamNot yet recruiting
  • Vanderbilt University Medical CenterNashville, United StatesContact: Terry WeyandNot yet recruiting
  • Hospital of the University of PennsylvaniaPhiladelphia, United StatesContact: Mary GnapNot yet recruiting
  • Intermountain HealthcareSalt Lake City, United StatesContact: Douglas L Packer, MDTaking people

About the trial

What the trial wants to find out

The Thermedical Ablation System and Durablate catheter is indicated for use in patients with recurrent, sustained, monomorphic ventricular tachycardia (SMVT) refractory to drug therapy and conventional (approved) catheter ablation.

Read full original descriptionShow less

Subjects with recurrent, SMVT refractory to drug therapy and conventional catheter ablation who are not eligible for, or will not likely benefit from repeat endocardial ablation using an approved catheter.

The group in the trial

  • Single arm treatmentTreatment being tested

    All subjects meeting inclusion/exclusion criteria and successfully consented will be treated with the study device.

    Treatment: Saline Enhanced Radiofrequency (SERF) Ablation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Saline Enhanced Radiofrequency (SERF) Needle Ablation for Refractory VT
Plain-language title
Saline-enhanced needle ablation for ventricular tachycardia that other treatments have not controlledGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
14 August 2025